新华财经上海12月16日电（记者潘清、杜康）在我国人口老龄化加速的背景下，心血管疾病高发对相关 诊疗行业发展提出更高要求。上海创新型高端医疗器械企业微创医疗16日宣布，通过推进业务整合，加 快构建全球化心衰专业器械平台。 微创心律管理是全球少数拥有完整心律管理产品线的企业之一，产品覆盖心脏起搏器、植入式心脏复律 除颤器（ICD）、心脏再同步治疗除颤器（CRT-D）、导线、心律管理患者监护仪及心律不齐诊断器械 等。 依托此次合并，微创心通将整合形成"结构性心脏病+心律管理+心衰管理"三位一体的综合平台。后续 通过渠道协同、运营提效以及持续的研发投入与全球化拓展，新平台的盈利能力有望实现稳步持续提 升。 微创医疗在港交所发布的自愿公告显示，12月15日微创心通召开股东大会，审议通过并购微创心律管理 有限公司的重大资产重组议案。此次并购将推动微创医疗旗下结构性心脏病与心律管理两大核心业务板 块的深度整合，面向心衰全病因、覆盖病程全阶段的复杂诊疗需求，加速构建贯穿"监测—诊断—治疗 —管理"全过程的全球化心衰专业器械平台。 值得注意的是，微创心通收购微创心律管理采取"零现金"换股方式，避免大额现金支出对微创心通运营 ...

Core Viewpoint - The company reported a revenue of 229 million, reflecting a year-on-year increase of 2.67%, while the loss attributable to equity shareholders decreased by 96.17% to 2.163 million [1] Financial Performance - Revenue for the six months ending June 30, 2025, was 229 million, up 2.67% year-on-year [1] - Loss attributable to equity shareholders was 2.163 million, a significant reduction of 96.17% compared to the previous year [1] - Basic loss per share was 0.09 cents [1] Business Development - The increase in revenue was primarily driven by the ongoing global commercialization of the VitaFlow Liberty transcatheter aortic valve and its retrievable delivery system, which significantly boosted overseas revenue [1] - The commercialization progress of the AnchorMan left atrial appendage occlusion system and the AnchorMan left atrial appendage guiding system in both China and overseas markets is steadily advancing [1]